VERA - Vera Therapeutics, Inc.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares of Class A common stock and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

May 08, 2026 12:05 PM • globenewswire.com

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory approval Strong balance sheet expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch BRISBANE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2026.

May 07, 2026 03:30 AM • globenewswire.com

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026.

May 04, 2026 03:30 AM • globenewswire.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock to eighty-nine (89) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Apr 10, 2026 12:30 PM • globenewswire.com

JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA

JPMorgan Chase and Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ: VERA) by 73.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,365 shares of the company's stock after selling 228,182 shares during the period. JPMorgan

Apr 07, 2026 01:03 AM • defenseworld.net

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.

Apr 01, 2026 03:35 AM • 247wallst.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A common stock to Jane Wright-Mitchell, Vera's new Chief Legal Officer under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Mar 27, 2026 12:05 PM • globenewswire.com

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D.

Mar 25, 2026 03:30 AM • globenewswire.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ: VERA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the

Mar 21, 2026 10:30 PM • defenseworld.net

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year

Integral Health bought 100,000 Vera Therapeutics shares for an estimated $3.55 million in the fourth quarter. Meanwhile, the quarter-end position value increased by $41.75 million, reflecting both share additions and stock price movements.

Mar 20, 2026 09:49 AM • fool.com

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment

Eversept Partners added 264,468 shares of Vera Therapeutics in the fourth quarter; the estimated transaction value was $9.39 million based on quarterly average pricing. Meanwhile, the quarter-end position value increased in value by $73.99 million, reflecting both trading and stock price movement.

Mar 16, 2026 10:03 AM • fool.com

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new shares held and price appreciation.

Mar 13, 2026 06:36 AM • fool.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Mar 06, 2026 11:05 AM • globenewswire.com

Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 06, 2026 10:05 AM • seekingalpha.com

Vera Therapeutics Appoints Christopher Hite to Board of Directors

BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors.

Mar 05, 2026 04:00 AM • globenewswire.com

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026 Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025.

Feb 26, 2026 02:30 AM • globenewswire.com

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

Feb 24, 2026 03:00 AM • globenewswire.com

Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

Vera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space. VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026. Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing.

Feb 20, 2026 11:00 AM • seekingalpha.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Feb 06, 2026 11:05 AM • globenewswire.com

Comparing Vera Therapeutics (NASDAQ:VERA) & Inventiva (NASDAQ:IVA)

Inventiva (NASDAQ: IVA - Get Free Report) and Vera Therapeutics (NASDAQ: VERA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current ratings

Feb 04, 2026 08:18 PM • defenseworld.net

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI

$91.00 (was $38.54)

Evercore ISI

May 15, 2026 08:25 AM • TheFly

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

$95.00 (was $47.69)

Goldman Sachs

Dec 19, 2025 07:20 AM • TheFly

Vera Therapeutics price target raised to $33 from $23 at Wedbush

$33.00 (was $45.42)

Laura Chico · Wedbush

Dec 11, 2025 08:21 AM • TheFly

Vera Therapeutics price target raised to $97 from $75 at Evercore ISI

$97.00 (was $45.78)

Gavin Clark-Gartner · Evercore ISI

Dec 08, 2025 08:34 AM • TheFly

Vera Therapeutics (VERA) PT Raised to $73 at TD Cowen

$73.00 (was $42.61)

Pivotal Research

Dec 05, 2025 04:49 AM • StreetInsider

H.C. Wainwright Reiterates Buy Rating on Vera Therapeutics (VERA)

$90.00 (was $33.33)

H.C. Wainwright

Nov 28, 2025 06:35 AM • StreetInsider

Vera Therapeutics price target raised to $65 from $55 at Scotiabank

$65.00 (was $30.91)

Greg Harrison · Scotiabank

Jun 03, 2025 10:03 AM • TheFly

Vera Therapeutics (VERA) PT Raised to $34 at Wedbush

$34.00 (was $42.87)

Laura Chico · Wedbush

Mar 21, 2024 02:01 AM • StreetInsider

Raymond James Upgrades Vera Therapeutics (VERA) to Strong Buy

$37.00 (was $30.18)

Ryan Deschner · Raymond James

Jan 26, 2024 01:47 AM • StreetInsider

Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst

$29.00 (was $15.84)

Ryan Deschner · Raymond James

Dec 18, 2023 08:59 AM • Benzinga

Jefferies Downgrades Vera Therapeutics to Hold, Lowers Price Target to $6

$6.00 (was $6.37)

Jefferies

Jan 04, 2023 05:29 AM • Benzinga

HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $15

$15.00 (was $18.30)

H.C. Wainwright

Jan 04, 2023 01:42 AM • Benzinga

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $38

$38.00 (was $17.62)

J.P. Morgan

Nov 18, 2022 03:12 AM • Benzinga

HC Wainwright & Co. Initiates Coverage On Vera Therapeutics with Buy Rating, Announces Price Target of $35

$35.00 (was $20.00)

H.C. Wainwright

May 02, 2022 02:06 AM • Benzinga